...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious diseases in obstetrics and gynecology >Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
【24h】

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.

机译：厄他培南每天一次，哌拉西林他唑巴坦每6小时一次，用于治疗急性盆腔感染：一项前瞻性，多中心，随机，双盲研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To compare ertapenem therapy with piperacillin-tazobactam therapy for the management of acute pelvic infections. METHODS: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin-tazobactam, 3.375 g every 6 hours, both administered intravenously. RESULTS: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin-tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli. At the primary efficacy endpoint 2-4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin-tazobactam were cured (95% confidence interval for the difference, adjusting for strata, -4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups. CONCLUSIONS: In this study, ertapenem was as effective as piperacillin-tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin-tazobactam.
机译：目的：比较厄他培南与哌拉西林-他唑巴坦治疗急性盆腔感染的方法。方法：在一项多中心，双盲研究中，将412例急性盆腔感染的妇女分配到产科/产后感染或妇科/术后感染这两个阶层之一，然后随机分为厄他培南，每天1克或哌拉西林他唑巴坦每6小时服用3.375克，均静脉内给药。结果：厄他培南组163例，哌拉西林-他唑巴坦组153例可进行临床评价。两个治疗组的中位治疗时间均为4.0天。最常见的单一病原体是大肠杆菌。在治疗后2-4周的主要疗效终点，治愈了93.9％的接受厄他培南的患者和91.5％的患者接受了哌拉西林-他唑巴坦的治愈（差异的95％置信区间，调整分层，-4％至8.8％ ），表明两个治疗组的治愈率是相同的。当按感染的程度和严重程度进行比较时，两个治疗组的治愈率也相似。两组中与药物相关的不良事件的发生频率和严重程度通常相似。结论：在这项研究中，厄他培南在治疗急性盆腔感染方面与哌拉西林-他唑巴坦一样有效，一般耐受性良好，总体安全性与哌拉西林-他唑巴坦相似。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号